(4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-[5-isopropyl-6-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl]-amine | 651744-07-9

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: (4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-[5-isopropyl-6-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl]-amine
• 英文别名: N-(4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-6-(5-methyl-1,3,4-oxadiazol-2-yl)-5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine
• CAS: 651744-07-9
• 化学式: C₂₀H₁₉FN₈O
• 分子量: 406.422
• InChiKey: IXYUGLGTMIXVHB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  在 四丁基氟化铵 作用下， 生成 (4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-[5-isopropyl-6-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl]-amine
  参考文献：
  名称：

  Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor

  摘要：

  We report herein a series of substituted N-(1H-pyrrolo[2,3-b] pyridin-5-yl) pyrrolo[2,1-f][1,2,4] triazin-4-amines as inhibitors of vascular endothelial growth factor receptor-2 tyrosine kinase. Through structure-activity relationship studies, biochemical potency, pharmacokinetics, and kinase selectivity were optimized to afford BMS-645737 (13), a compound with good preclinical in vivo activity against human tumor xenograft models. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.03.057

文献信息

• [EN] AZAINDOLE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE L'AZAINDOLE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2004009601A1

  公开（公告）日：2004-01-29

  The present invention provides compounds of formula (I), (I) and pharmaceutically acceptable salts thereof.The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula (I) compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明提供式（I）的化合物，式（I）的药物可接受的盐。式（I）化合物抑制生长因子受体的酪氨酸激酶活性，如VEGFR-2和FGFR-1，因此使它们可用作抗癌剂。式（I）化合物也适用于治疗通过生长因子受体操作的信号转导途径引起的其他疾病。
• Azaindole kinase inhibitors
  申请人：Bhide S. Rajeev

  公开号：US20060058304A1

  公开（公告）日：2006-03-16

  The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明提供了I式化合物及其药学上可接受的盐。I式化合物抑制生长因子受体如VEGFR-2和FGFR-1的酪氨酸激酶活性，因此可用作抗癌剂。I式化合物还可用于治疗与通过生长因子受体进行信号转导途径相关的其他疾病。
• AZAINDOLE KINASE INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1539763B1

  公开（公告）日：2011-04-13
• EP1539763A4
  申请人：——

  公开号：EP1539763A4

  公开（公告）日：2007-08-01
• US6969717B2
  申请人：——

  公开号：US6969717B2

  公开（公告）日：2005-11-29